Costs and healthcare utilisation of patients with heart failure in Spain

BMC Health Services Research

Luis Varela¹  Beatriz Palacios¹  Margarita Capel¹  Antoni Sicras²  Aram Sicras²  Manuel Botana³  Nicolás Manito⁴  Antonio Hormigo⁵  Roberto Alcázar⁶  Carlos Escobar⁷ 

[1] AstraZeneca Spain, Barcelona, Spain;Health Economics and Outcomes Research, Atrys Health, Barcelona, Spain;Hospital Universitario Lucus Augusti, Lugo, Spain;Hospital de Bellvitge, Hospitalet de Llobregat, Barcelona, Spain;Primary Care Center Salud Puerta Blanca, Malaga, Spain;University Hospital Infanta Leonor, Madrid, Spain;University Hospital La Paz, Madrid, Spain;

关键词: Heart failure cost;    Dapagliflozin;    DAPA-HF;    Heart failure;    Hospitalization;    Sacubitril/valsartan;   

DOI  :  10.1186/s12913-020-05828-9

来源: Springer

【 摘 要 】

BackgroundIncreasing the knowledge about heart failure (HF) costs and their determinants is important to ascertain how HF management can be optimized, leading to a significant decrease of HF costs. This study evaluated the cumulative costs and healthcare utilisation in HF patients in Spain.MethodsObservational, retrospective, population-based study using BIG-PAC database, which included data from specialized and primary care of people ≥18 years, from seven autonomous communities in Spain, who received care for HF between 2015 and 2019. The healthcare and medication costs were summarized on a yearly basis starting from the index date (1st January 2015), and then cumulatively until 2019.ResultsWe identified 17,163 patients with HF (year 2015: mean age 77.3 ± 11.8 years, 53.5% men, 51.7% systolic HF, 43.6% on NYHA functional class II). During the 2015–2019 period, total HF associated costs reached 15,373 Euros per person, being cardiovascular disease hospitalizations the most important determinant (75.8%), particularly HF hospitalizations (51.0%). Total medication cost accounted for 7.0% of the total cost. During this period, there was a progressive decrease of cardiovascular disease hospital costs per year (from 2834 Euros in 2015 to 2146 Euros in 2019, P < 0.001), as well as cardiovascular and diabetic medication costs.ConclusionsDuring the 2015–2019 period, costs of HF patients in Spain were substantial, being HF hospitalizations the most important determinant. Medication costs represented only a small proportion of total costs. Improving HF management, particularly through the use of drugs that reduce HF hospitalization may be helpful to reduce HF burden.

【 授权许可】

CC BY